307 related articles for article (PubMed ID: 11001887)
1. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
Koshy M; Dorn L; Bressler L; Molokie R; Lavelle D; Talischy N; Hoffman R; van Overveld W; DeSimone J
Blood; 2000 Oct; 96(7):2379-84. PubMed ID: 11001887
[TBL] [Abstract][Full Text] [Related]
2. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.
DeSimone J; Koshy M; Dorn L; Lavelle D; Bressler L; Molokie R; Talischy N
Blood; 2002 Jun; 99(11):3905-8. PubMed ID: 12010787
[TBL] [Abstract][Full Text] [Related]
3. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.
Saunthararajah Y; Hillery CA; Lavelle D; Molokie R; Dorn L; Bressler L; Gavazova S; Chen YH; Hoffman R; DeSimone J
Blood; 2003 Dec; 102(12):3865-70. PubMed ID: 12907443
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production.
Dover GJ; Humphries RK; Moore JG; Ley TJ; Young NS; Charache S; Nienhuis AW
Blood; 1986 Mar; 67(3):735-8. PubMed ID: 2418898
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
Charache S; Dover GJ; Moore RD; Eckert S; Ballas SK; Koshy M; Milner PF; Orringer EP; Phillips G; Platt OS
Blood; 1992 May; 79(10):2555-65. PubMed ID: 1375104
[TBL] [Abstract][Full Text] [Related]
7. 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens.
Dover GJ; Charache S; Boyer SH; Vogelsang G; Moyer M
Blood; 1985 Sep; 66(3):527-32. PubMed ID: 2411310
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
Rodgers GP
Semin Oncol; 1992 Jun; 19(3 Suppl 9):67-73. PubMed ID: 1379375
[TBL] [Abstract][Full Text] [Related]
9. Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease.
Saunthararajah Y; DeSimone J
Semin Hematol; 2004 Oct; 41(4 Suppl 6):11-6. PubMed ID: 15534852
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S
Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
[TBL] [Abstract][Full Text] [Related]
11. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
12. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
Molokie R; Lavelle D; Gowhari M; Pacini M; Krauz L; Hassan J; Ibanez V; Ruiz MA; Ng KP; Woost P; Radivoyevitch T; Pacelli D; Fada S; Rump M; Hsieh M; Tisdale JF; Jacobberger J; Phelps M; Engel JD; Saraf S; Hsu LL; Gordeuk V; DeSimone J; Saunthararajah Y
PLoS Med; 2017 Sep; 14(9):e1002382. PubMed ID: 28880867
[TBL] [Abstract][Full Text] [Related]
13. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
Borba R; Lima CS; Grotto HZ
J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
[TBL] [Abstract][Full Text] [Related]
14. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.
Steinberg MH; Lu ZH; Barton FB; Terrin ML; Charache S; Dover GJ
Blood; 1997 Feb; 89(3):1078-88. PubMed ID: 9028341
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.
Rivers A; Vaitkus K; Jagadeeswaran R; Ruiz MA; Ibanez V; Ciceri F; Cavalcanti F; Molokie RE; Saunthararajah Y; Engel JD; DeSimone J; Lavelle D
Exp Hematol; 2018 Nov; 67():60-64.e2. PubMed ID: 30125603
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease.
Atweh GF; Schechter AN
Curr Opin Hematol; 2001 Mar; 8(2):123-30. PubMed ID: 11224687
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic manipulation of fetal hemoglobin synthesis.
Dover GJ; Humphries RK; Young N; Ley T; Boyer S; Charache S; Nienhuis A
Prog Clin Biol Res; 1985; 191():447-54. PubMed ID: 2413480
[TBL] [Abstract][Full Text] [Related]
18. Determinants of fetal hemoglobin response to hydroxyurea.
Steinberg MH
Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
[TBL] [Abstract][Full Text] [Related]
19. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex.
Charache S; Dover G; Smith K; Talbot CC; Moyer M; Boyer S
Proc Natl Acad Sci U S A; 1983 Aug; 80(15):4842-6. PubMed ID: 6192443
[TBL] [Abstract][Full Text] [Related]
20. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
